Tumor-targeted gene delivery of tumor necrosis factor-α induces tumor necrosis and tumor regression without systemic toxicity

Cancer Gene Therapy

Volumn 9, Issue 8, 2002, Pages 673-680

  Kircheis, Ralf ^a   Ostermann, Elinborg ^a   Wolschek, Markus F ^b,c   Lichtenberger, Cornelia ^c   Magin Lachmann, Christine ^a   Wightman, Lionel ^a   Kursa, Malgorzata ^a   Wagner, Ernst ^a  

^a BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Gene therapy; Nonviral gene transfer; PEI; Polyethylenimine; TNF ; Transferrin; Tumor necrosis factor; Tumor targeting

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; DNA; POLYETHYLENEIMINE; TRANSFERRIN;

ANIMAL; ARTICLE; CELL CULTURE; EXPERIMENTAL MELANOMA; FIBROSARCOMA; GENE THERAPY; GENETICS; METABOLISM; MOUSE; NEUROBLASTOMA; PATHOLOGY; ANIMAL MODEL; CANCER INHIBITION; GENE TARGETING; GENE TRANSFER; MELANOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; TOXICITY; TUMOR NECROSIS; TUMOR REGRESSION;

ANIMALS; FIBROSARCOMA; GENE THERAPY; MELANOMA, EXPERIMENTAL; MICE; NEUROBLASTOMA; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; ANIMAL; TUMOR NECROSIS FACTOR;

ANIMALIA; MURINAE;

EID: 0036021898     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700487     Document Type: Article

References (38)

1. Gene transfer with synthetic cationic amphiphiles: Prospects for gene therapy
2. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations
3. Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes
4. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo - Polyethylenimine
5. Polycation-based DNA complexes for tumor-targeted gene delivery in vivo
6. PEGylated DNA/Transferrin-PEI complexes: Reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery
7. Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application
8. An endotoxin-induced serum factor that causes necrosis of tumors
9. Tumor necrosis factor (TNF)
10. Toxic effect of tumor necrosis factor on tumor vasculature in mice
11. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha)
12. Macroscopic and microscopic early effects of tumor necrosis factor on murine MethA sarcoma, and relation to curative activity
13. Activation of human polymorphonuclear neutrophil functions by interferon-γ and tumor necrosis factor
14. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: Induction of TNF receptors on human T cells and TNF-alpha mediated enhancement of T cell responses
15. Interleukin-1, interleukin-6 and tumor necrosis factor in infection, inflammation and immunity
16. Recombinant tumor necrosis factor-α: Effect on proliferation of normal and transformed cells in vitro
17. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin
18. Cachectin and tumor necrosis factor as two sides of the same biological coin
19. Tumor necrosis factor causes microvascular protein leakage independently of neutrophils or mast cells
20. Concanavalin A hepatotoxicity in mice: Tumor necrosis factor-mediated organ failure independent of caspase-3-like protease activation
21. Biological activity of mutants of human tumour necrosis factor-alpha
22. A human tumor necrosis factor (TNF) alpha mutant that binds exclusively to the p55 TNF receptor produces toxicity in the baboon
23. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience
24. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan
25. Polyethylenimine-based intravenous delivery of transgenes to mouse lung
26. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth
27. Differences in the biological activity of TNFα and TNFβ correlate with their different abilities for binding to the target cells
28. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: Phase I toxicity and effects on lipid metabolism
29. Phase II clinical trial of high-dose recombinant human tumor necrosis factor
30. A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days
31. Tumor Necrosis Factor α-mediated tumor regression by the in vivo transfer of genes into the artery that leads to tumors
32. Tumour therapy in mice using adenovirus vectors expressing human TNFα
33. Polycation/DNA complexes for in vivo gene delivery
34. Microvascular permeability of normal and neoplastic tissue
35. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
36. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy
37. Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor mediated endocytosis
38. Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery